Hims & Hers Health (HIMS): Navigating the Upcoming Earnings Report
The telehealth sector is witnessing a fascinating evolution, and at the centre of the conversation is Hims & Hers Health (NYSE: HIMS). With the company set to report its latest financial results this Monday after the closing bell, investors are questioning whether the current momentum is sustainable or if a correction is looming.
If you are tracking Hims stock, understanding the balance between rapid growth and market expectations is key to making an informed decision.
A Look Back: Growth vs. Guidance
In the previous quarter, Hims & Hers Health demonstrated strong top-line growth, reporting revenues of $617.8 million, representing a impressive 28.4% increase year-over-year. The company also expanded its user base, adding 40,000 new customers to reach a total of 2.51 million.
However, the narrative was mixed. While the full-year revenue guidance exceeded analyst expectations, the outlook for the following quarter fell significantly short, creating a sense of uncertainty among short-term traders.
What to Expect in the Next Earnings Call
The market is now bracing for a potential slowdown. Here are the critical data points to watch:
- n
- Projected Revenue Growth: Analysts expect revenue to grow by approximately 5.2% year-over-year. This is a sharp deceleration compared to the 111% surge recorded during the same period last year.
- Wall Street’s Track Record: Historically, Hims & Hers Health has struggled to consistently hit revenue estimates over the last two years, making this upcoming report a critical test of its stability.
- Analyst Sentiment: Most analysts have maintained their estimates over the last 30 days, suggesting a “wait and see” approach as the company maintains its current course.
Contextualizing HIMS: Peer Performance in Health-Tech
To understand the potential volatility of Hims stock, it is helpful to look at its peers in the NYSE healthcare technology segment. Recent results from other players show that beating expectations doesn’t always guarantee a price jump:
- GoodRx: Reported a 4.4% revenue decrease but beat analyst estimates by 4.9%, resulting in a 9.9% stock price increase.
- Tandem Diabetes: Topped estimates with a 5.5% revenue increase, yet saw its share price drop by 16.3%.
This volatility highlights that the market is valuing more than just the numbers; it is valuing future guidance and strategic execution.
Market Sentiment and Valuation Gap
There is currently a bullish trend in the healthcare tech sector, with shares up an average of 6.1% over the last month. Hims & Hers Health has drastically outperformed this trend, soaring 49.6% in the same period.
However, there is a notable gap between the current market price and professional valuations. With the stock trading around $29.07, it sits well above the average analyst price target of $26.04. This suggests that the stock may be overextended heading into the earnings announcement.
Final Verdict: Buy or Sell?
Whether Hims stock is a buy or a sell depends on your risk tolerance. The company is growing its customer base and revenue, but the deceleration in growth rates and the current premium price point create a high-risk, high-reward scenario.
Investors should keep a close eye on the revenue guidance provided during the call, as this will likely be the primary driver of the stock’s movement in the coming days.
